Aadi Bioscience, Inc.

NasdaqCM:AADI Rapport sur les actions

Capitalisation boursière : US$56.2m

Aadi Bioscience Gestion

Gestion contrôle des critères 2/4

Le PDG Aadi Bioscience est Dave Lennon, nommé en Oct2023, a un mandat de 1.08 ans. La rémunération annuelle totale est $ 2.14M, composée du salaire de 7.5% et des bonus 92.5%, y compris les actions et options de la société. détient directement 0.093% des actions de la société, d'une valeur de $ 52.14K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.4 ans et 3.3 ans.

Informations clés

Dave Lennon

Directeur général

US$2.1m

Rémunération totale

Pourcentage du salaire du PDG7.5%
Durée du mandat du directeur général1.1yrs
Propriété du PDG0.09%
Durée moyenne d'occupation des postes de direction2.4yrs
Durée moyenne du mandat des membres du conseil d'administration3.3yrs

Mises à jour récentes de la gestion

Recent updates

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Jul 03
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Jul 02
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10
Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07
Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12
Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16
Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10
Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Sep 28
A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Sep 21

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Jul 06
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Jun 23

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27
What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

Analyse de la rémunération des PDG

Comment la rémunération de Dave Lennon a-t-elle évolué par rapport aux bénéfices de Aadi Bioscience?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$62m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$160k

-US$66m

Rémunération vs marché: La rémunération totale de Dave ($USD 2.14M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 650.80K ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Dave avec les performances de l'entreprise.

PDG

Dave Lennon (53 yo)

1.1yrs

Titularisation

US$2,135,687

Compensation

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Équipe de direction

NomPositionTitularisationCompensationPropriété
David Lennon
President1.1yrsUS$2.14m0.093%
$ 52.1k
Scott Giacobello
CFO, Treasurer3yrsUS$1.97m0%
$ 0
Stephen Rodin
Senior VP of Legal & General Counsel2.8yrspas de donnéespas de données
Raymond Steitz
Senior VP of Human Resources & Chief Human Resources Officer2.4yrspas de donnéespas de données
Bryan Ball
Chief Technical Operations Officer2.3yrspas de données0.41%
$ 228.0k

2.4yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe de direction de AADI est considérée comme expérimentée (ancienneté moyenne 2.4 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
David Lennon
President1.1yrsUS$2.14m0.093%
$ 52.1k
Caley Castelein
Independent Chairman of the Board3.3yrsUS$258.91k0.080%
$ 44.9k
Emma Reeve
Independent Director3.2yrsUS$240.91k0%
$ 0
Anupam Dalal
Independent Director3.3yrsUS$235.91k0.0046%
$ 2.6k
Karin Hehenberger
Independent Director3.3yrsUS$227.41k0%
$ 0
Richard Maroun
Independent Director7.8yrsUS$240.91k0%
$ 0
Mohammad Hirmand
Independent Director1.7yrsUS$345.60k0%
$ 0
Behzad Aghazadeh
Independent Director3.3yrsUS$225.41k0%
$ 0

3.3yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AADI sont considérés comme expérimentés (ancienneté moyenne 3.3 ans).